FibroBiologics (FBLG) vs Longeveron (LGVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Longeveron is the larger company by market cap ($7.9 million vs $7.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | LGVN |
|---|---|---|
| Share price | $1.13 | $2.48 |
| Market cap | $7.86M | $7.91M |
| 1-day change | +1.80% | +4.64% |
| EPS (TTM) | $-5.01 | $-9.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.98 | $12.30 |
| 52-week low | $0.62 | $2.30 |
| Distance from 52-week high | -88.68% | -79.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +1006.19% | +2369.76% |
| Average volume | 204.44K | 93.67K |
| Shares outstanding | 6.96M | 3.04M |
| Employees | 15 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
FBLG vs LGVN FAQ
Which is bigger, FibroBiologics or Longeveron?
Longeveron (LGVN) is larger, with a market capitalization of $7.91M compared with $7.86M for FibroBiologics (FBLG).
Are FibroBiologics and Longeveron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.